Tenaya Therapeutics (TNYA) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 27, 2026, to be held virtually for shareholders of record as of April 1, 2026.

• Proxy materials, including the notice, proxy statement, and annual report, are available online, with paper copies available upon request.

Voting matters and shareholder proposals

• Election of three Class II directors to serve until the 2029 annual meeting: Amy Burroughs, Karah Parschauer, and Catherine Stehman-Breen.

• Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Amendment and restatement of the 2021 Equity Incentive Plan to increase reserved shares by approximately 3% of outstanding shares and remove the 4 million annual share limit from the evergreen provision.

• Named proxies authorized to vote on additional business as may arise at the meeting.

Board of directors and corporate governance

• Board recommends voting FOR all director nominees and both additional proposals.